Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.
Michael Iglesia, MD, PhD, discusses uncertainties surrounding the selection of second-line treatment approaches in hepatocellular carcinoma.
Geoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.
Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.
Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.
Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine-lpyl in relapsed/refractory large B-cell lymphoma.
Domenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator in combination with nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum resistant ovarian cancer.
Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Amma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer
Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.
David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.
Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.
Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.
Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Bhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.
Leading researchers in rare blood cancers to investigate new therapeutic strategy that targets leukemic stem cells.
Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.
Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.
Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.